AndersonBDWygantMDXiangTXWaughWAStellaVJ. Preformulation solubility and kinetic studies of 2′,3′-dideoxyneucleosides: Potential anti-AIDS agents. Int J Pharm1988; 45: 27–37.
2.
ShyuWKnuppCAPittmanKADunkleLBarbhaiyaRH. Foodinduced reduction in bioavailability of didanosine. Clin Pharmacol Ther1991; 50: 503–7.
3.
HartmanNRYarchoanRPludaJMThomasRVWyvillKMFloraKP. Pharmacokinetics of 2′,3′-dideoxyinosine in patients with severe immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther1991; 50: 278–85.
4.
MetrokaCEMcMechanMFAndradaRLaubensteinLJJacobusDP. Failure of prophylaxis with dapsone in patients taking dideoxyinosine (letter). N Engl J Med1991; 325: 737.
5.
AhmadRARogersHJ. Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method. Eur J Clin Pharmacol1980; 17: 129–33.
6.
BlumRAD'AndreaDTFlorentinoBMWiltonJHHilligossDMGardnerMJ. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med1991; 114: 755–7.
7.
DaneshmendTKWarnockDW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet1988; 14: 13–34.
8.
NixDEWatsonWALenerMEFrostRWKrolGGoldsteinH. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther1989; 46: 700–5.
9.
NeuvonenPJKivistoKTLehtoP. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther1991; 50: 498–502.
10.
RichterWOJacobBGSchwandtP. Interaction between fibre and lovastatin (letter). Lancet1991; 338: 707.
11.
BaileyDGSpenceJDBayliffCDArnoldJMO. Ethanol enhances the hemodynamics effects of felodipine. Clin Invest Med1989; 12: 357–62.
12.
BaileyDGSpenceJKMunozCArnoldJMO. Interaction of citrus juices with felodipine and nifedipine. Lancet1991; 337: 268–9.
FunakiTSoonsPAGuengerichFPBreimerDD. In vitro oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. Biochem Pharmacol1989; 38: 4214–6.
15.
BueningMKChangRLHuangMTFortnerJGWoodAWConneyAH. Activation and inhibition of benzo(a)pyrene and aflatoxin B, metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res1981; 41: 67–72.
16.
MikusGFischerCHeuerBLangenCEichelbaumM. Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after iv and po administration. Br J Clin Pharmacol1987; 24: 561–9.
17.
SoonsPARoosemalenMCMBreimerDD. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy subjects. Eur J Pharmacol1990; 183: 2283–4.
18.
EltzeMBoerRSandersKHBossHUlrichWRFlockerziD. Stereoselective inhibition of thromboxane-induced coronary vasoconstriction by 1,4-dihydropyridine calcium channel antagonists. Chirality1990; 2: 233–4.
19.
SoonsPAVogelsBAPMRoosemalenMCMSchoemakerHCUchidaEEdgarB. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther1991; 50: 394–403.
20.
GuengerichFP. Characterization of human microsomal cytochrome P-450 enzymes. Ann Rev Pharmacol Toxicol1989; 29: 241–64.
21.
BertilssonLHenthornTKSanzETybringGSaweJVillenT. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin but not to debrisoquine hydroxylation phenotype. Clin Pharmacol Ther1989; 45: 348–55.
22.
AnderssonTRegardhCGDahl-PuustinenMLBertilssonL. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit1990; 12: 415–6.
23.
GuglerRJensenJC. Omeprazole inhibits oxidative drug metabolism—studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology1985; 89: 1235–41.
24.
AnderssonTCederbergCEdvardssonGHegelundALundborgP. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther1990; 47: 79–85.
25.
BaciewiczAMSelfTH. Rifampin drug interactions. Arch Intern Med1984; 144: 1667–71.
26.
EichelbaumMMineshitaSOhnhausEEZekornC. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol1986; 22: 49–53.
27.
ZhouHHAnthonyLBWoodAJJWilkinsonGR. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol1990; 30: 471–5.
28.
GonzalezFJ. The molecular biology of cytochrome P450s. Pharmacol Rev1989; 40: 243–88.
29.
WedlundPJAslanianWSJacqzEMcAllisterCDBranchRAWilkinsonGR. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther1985; 234: 662–9.
30.
KnodellRGBubeyRKWilkinsonGRGuengerichFP. Oxidative metabolism of hexobarbital in human liver: Relation to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther1988; 245: 845–9.
31.
ZillyWBreimerDDRichterE. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol1975; 9: 219–27.
32.
HeinemeyerGGrammHJSimgenWDennhardtRRootsI. Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital. Eur J Clin Pharmacol1987; 32: 273–7.
33.
JacqzEHallSDBranchRAWilkinsonGR. Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a coregulated substrate, mephobarbital. Clin Pharmacol Ther1986; 39: 646–53.
34.
LeskoLJ. Pharmacokinetic drug interactions with amiodarone. Clin Pharmacokinet1989; 17: 130–40.
35.
Funck-BrentanoCJacqz-AigrainELeenhardtARouxAPoirierJMJaillonP. Influence of amiodarone on genetically determined drug metabolism in humans. Clin Pharmacol Ther1991; 50: 259–66.
36.
HallSDGuengerichFPBranchRAWilkinsonGR. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther1987; 240: 216–22.
37.
AtibaJOBlaschkeTFWilkinsonGR. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. Br J Clin Pharmacol1989; 28: 161–5.
38.
WedlundPJAslanianWSMcAllisterCDWilkinsonGRBranchRA. Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther1984; 36: 773–80.
39.
DoeckeCJVeroneseMEPondSMMinersJOBirkettDJSansomLN. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol1991; 31: 125–30.
40.
DickinsonRGHooperWDPattersonMEadieMJMaguireB. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit1985; 7: 283–9.
41.
ThomasRCIkedaGJ. The metabolic fate of tolbutamide in man and in the rat. J Med Chem1966; 9: 507–10.
42.
VeroneseMEMinersJORandlesDGregovDBirkettDJ. Validation of the tolbutamide metabolic ratio for population screening using sulfphaphenazole to produce model phenotypic poor metabolisers. Clin Pharmacol Ther1990; 47: 403–11.
